Serum levels of VEGF and bFGF in infantile hemangiomas treated with propranolol
Background. Infantile hemangiomas (IH) represent the most common type of benign tumors of infancy. Vascular endothelial growth factor (VEGF) and basic fibroblastic growth factor (bFGF) have a central role in the pathogenesis of infantile hemangiomas.Methods. In this prospective study, we aimed to investigate the relationship between serum VEGF and bFGF levels and clinical characteristics and the serological changes in VEGF and bFGF levels associated with propranolol treatment in infants diagnosed with IH. Blood samples were taken from 34 patients with IH and 10 controls. Serum VEGF and bFGF levels were studied by ELISA.Results. At initial diagnosis, median serum bFGF levels were 11.1 ng/ml (4.8-16.6) in patients with IH (n=34) and 2.6 ng/ml (1.7-4.7) in controls (p
___
1. Ma X, Zhao T, Xiao Y, et al. Preliminary experience on treatment of infantile hemangioma with lowdose propranolol in China. Eur J Pediatr 2013; 172: 653-659.2. Smolinski KN, Yan AC. Hemangiomas of infancy: clinical and biological characteristics. Clin Pediatr (Phila) 2005; 44: 747-766.
3. Hagen R, Ghareeb E, Jalali O, Zinn Z. Infantile hemangiomas: what have we learned from propranolol? Curr Opin Pediatr 2018; 30: 499-504.
4. Folkman J. Clinical application of research on angiogenesis. N Engl J Med 1995; 333: 1757 1763
5. Przewratil P, Sitkiewicz A, Andrzejewska E. Serum levels of basic fibroblastic growth factor (bFGF) in children with vascular anomalies: another insight into endothelial growth. Clin Biochem 2010; 43: 863- 867.
6. Wu S, Wang B, Chen L, et al. Clinical efficacy of propranolol in the treatment of hemangioma and changes in serum VEGF, bFGF and MMP-9. Exp Ther Med 2015; 10: 1079-1083.
7. Krowchuk DP, Frieden IJ, Mancini AJ, et al; Subcommittee on the management of infantile hemangiomas Clinical practice guideline for the management of infantile hemangiomas. Pediatrics 2019; 143: e20183475.
8. Satterfield KR, Chambers CB. Current treatment and management of infantile hemangiomas. Surv Ophthalmol 2019; 64: 608-618.
9. Yang H, Hu DL, Shu Q, Guo XD. Efficacy and adverse effects of oral propranolol in infantile hemangioma: a meta-analysis of comparative studies. World J Pediatr 2019; 15: 546-558.
10. Achauer BM, Chang CJ, Vander Kam VM. Management of hemangioma of infancy: review of 245 patients. Plast Reconstr Surg 1997; 99: 1301-1308. 11. Gupta K, Zhang J. Angiogenesis: a curse or cure? Postgrad Med J 2005; 81: 236-242.
12. Zhang L, Mai HM, Zheng J, et al. Propranolol inhibits angiogenesis via down-regulating the expression of vascular endothelial growth factor in hemangioma derived stem cell. Int J Clin Exp Pathol 2014; 7: 48-55.
13. Przewratil P, Sitkiewicz A, Wyka K, Andrzejewska E. Serum levels of vascular endothelial growth factor and basic fibroblastic growth factor in children with hemangiomas and vascular malformationspreliminary report. Pediatr Dermatol 2009; 26: 399- 404.
14. Frischer JS, Huang J, Serur A, Kadenhe A, Yamashiro DJ, Kandel JJ. Biomolecular markers and involution of hemangiomas. J Pediatr Surg 2004; 39: 400-404.
15. Zhang L, Lin X, Wang W, et al. Circulating level of vascular endothelial growth factor in differentiating hemangioma from vascular malformation patients. Plast Reconstr Surg 2005; 116: 200-204.
16. Zhang L, Chen Q, Li D, Li XW, Wang HG, Li GZ. Evaluation of the role of serum vascular endothelial growth factor and urinary basic fibroblast growth factor in differential diagnosis of vascular anomalies. Zhonghua Yi Xue Za Zhi 2011; 91: 1092-1095.
17. Yuan WL, Jin ZL, Wei JJ, Liu ZY, Xue L, Wang XK. Propranolol given orally for proliferating infantile haemangiomas: analysis of efficacy and serological changes in vascular endothelial growth factor and endothelial nitric oxide synthase in 35 patients. Br J Oral Maxillofac Surg 2013; 51: 656-661.
18. Chen XD, Ma G, Huang JL, et al. Serum-level changes of vascular endothelial growth factor in children with infantile hemangioma after oral propranolol therapy. Pediatr Dermatol 2013; 30: 549-553.
19. Ozeki M, Nozawa A, Hori T, et al. Propranolol for infantile hemangioma: effect on plasma vascular endothelial growth factor. Pediatr Int 2016; 58: 1130- 1135.
20. El-Raggal NM, El-Farrash RA, Saad AA, Attia EAS, Saafan HA, Shaaban IS. Circulating levels of vascular endothelial growth factor and basic fibroblastic growth factor in infantile hemangioma versus vascular malformations. Clin Appl Thromb Hemost 2018; 24: 663-668
21. Yang XJ, Jiang YH, Zheng JW, Hong L, Zhou Q, Qin ZP. The role of serum basic fibroblast growth factor, estradiol and urine basic fibroblast growth factor in differentiating infantile haemangiomas from vascular malformations. Phlebology 2011; 26: 191-196.
22. Babiak-Choroszczak L, Giżewska-Kacprzak K, Gawrych E, et al. Serum concentrations of VEGF and bFGF in the course of propranolol therapy of infantile hemangioma in children :are we closer to understand the mechanism of action of propranolol on hemangiomas? Adv Clin Exp Med 2018; 27: 703- 710.
23. Zhang L, Lin XX, Qi ZL, et al. Role of urinary basic fibroblast growth factor in differentiating hemangiomas from vascular malformation. Zhonghua Wai Ke Za Zhi 2006; 44: 186-188.
24. Léaute-Labrèze C, Boccara O, Degrugillier-Chopinet C, et al. Safety of oral propranolol for the treatment of infantile hemangioma: a systematic review. Pediatrics 2016; 138: e20160353.
25. Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J, et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med 2015; 372: 735-746.
26. Chen ZY, Wang QN, Zhu YH, et al. Progress in the treatment of infantile hemangioma. Ann Transl Med 2019; 7 :692.
27. Przewratil P, Kobos J, Wnęk A, et al. Serum and tissue profile of VEGF and its receptors VGFR1/R2 in children with infantile hemangiomas on systemic propranolol treatment. Immunol Lett 2016; 175: 44- 49.
28. Rotter A, de Oliveira ZNP. Infantile hemangioma: pathogenesis and mechanisms of action of propranolol. J Dtsch Dermatol Ges 2017; 15: 1185- 1190.
29. Storch CH, Hoeger PH. Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. Br J Dermatol 2010; 163: 269- 274.
30. Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taieb A. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008; 358: 2649-2651
- ISSN: 0041-4301
- Yayın Aralığı: Yılda 6 Sayı
- Başlangıç: 1958
- Yayıncı: Hacettepe Üniversitesi Çocuk Sağlığı Enstitüsü Müdürlüğü
Sayıdaki Diğer Makaleler
The effect of warts on quality of life in Turkish pediatric patients
Neslihan AKDOĞAN, Sema KOÇ YILDIRIM, Sibel ERSOY EVANS, S. Ebru ÇENGEL KÜLTÜR
Life-stage factors associated with overweight severity inadolescents
Raziye Dut, Antonio Videira-Silva, Ana Sofia Vilardouro, Silvia Freira, Helena Fonseca
Muhterem DUYU, Selin YILDIZ, İrem Deniz BULUT, Zeynep KARAKAYA, Ayşenur BUZ, Gülçin BOZBEYOĞLU
Serum levels of VEGF and bFGF in infantile hemangiomas treated with propranolol
Hilal SUSAM ŞEN, Bilgehan YALÇIN, Hande CANPINAR, Süheyla OCAKV, Canan AKYÜZ
Ahmed Fathy SAMHAN, Walid Kamal ABDELBASSET, Ragab Kamal ELNAGGAR
A rare pediatric case of neurobrucellosis with bilateral optic neuritis
Jale KARAKAYA, Meral HURİ, Hülya KAYIHAN, Elif N. ÖZMERT, Tuba ÇELEN YOLDAŞ
Determinants of outcomes in chronic pediatric peritoneal dialysis: a single center experience
Bora GÜLHAN, Ali DÜZOVA, Rezzan TOPALOĞLU, Fatih ÖZALTIN, Fazıl T. AKİ, Gökhan KARAKURT, Serdar TEKGÜL, Ali C. BOZACI, Tariq ASİİ, Hasan S. DOĞAN, Ömer F. BAHADIR
Neurocognitive abilities in individuals with Down syndrome-a narrative review